BUZZ-Organon rises on Q4 profit beat

Shares of healthcare company Organon OGN.N rise 11.2% to $16.34

The developer of drugs for women's health and biosimilars posts Q4 adjusted profit of 90 cents per share vs analysts' average estimate of 87 cents per share - data compiled by LSEG

Q4 revenue at $1.59 billion, in line with the estimate

"We expect a slightly positive stock reaction on Q4 EPS beat and better EBITDA guidance, as the revenue guidance was materially impacted by FX," says brokerage BNP Paribas Exane

Company forecasts 2025 revenue in the range of $6.13 billion to $6.33 billion, below analysts' estimate of $6.47 billion

OGN shares down ~3% in the last 12 months